Project Grant R01DE034377
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $156,000 Project Grant under the Oral Diseases and Disorders Research (CFDA 93.121) federal grant program to the University of Colorado-Denver. The grant will support a research project titled "Sex-Specific Immune Microenvironment in Oral Cancer" from July 1, 2025 to June 30, 2027. The research aims to investigate sex-specific differences in the immune microenvironment of head and neck squamous cell...
- This federal Project Grant award of $3,742,682 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Massachusetts. The grant supports research to dissect the role of the chemokine CCL5 in shaping antigen-specific T cell responses against head and neck cancers. Key objectives include: Investigating how CCL5 chemokine networks impact the development...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $219,660 Project Grant to the Regents of the University of Michigan to conduct research on "Intercepting the Evolution of Pro-Tumoral Myeloid Cells During the Initiation of Oral Cancer". This project aims to investigate how myeloid cells in precancerous lesions develop suppressive phenotypes that inhibit anti-tumor immune...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $616,000 Project Grant to the Rowan University School of Osteopathic Medicine. This grant, with a performance period from Aug 1, 2025 to Jul 31, 2029, will support research investigating the use of the Hedgehog signaling pathway inhibitor drug sonidegib as a potential therapeutic strategy for oral squamous cell carcinoma (OSCC). The key...
- This federal Project Grant award of $483,360.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will fund research to target vulnerabilities in the EGFR/HER3/HER2 oncogenic signaling circuitry for developing new precision therapies for oral cancer. The project aims to explore synthetic lethal and gene interaction networks to expose druggable systems vulnerabilities and uncover mechanisms of...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $298,942 Project Grant to Deltamed LLC on August 20, 2025. The grant funding will support the development of a novel "nanosponge prodrug delivery system" for the small molecule MK2 inhibitors apatinib and MMI-0100. The goal is to improve the circulation half-life and targeted delivery of these compounds to mitigate...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $390,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The Medical College of Wisconsin, Inc. The grant funds a 5-year research project to leverage single-cell co-culture and gene expression profiling to identify tumor antigen-specific T cells in oral squamous cell carcinoma (OSCC). The project aims to develop innovative methods to isolate and characterize tumor-infiltrating...
- This $642,488 Project Grant was awarded on June 10, 2025 by the National Institute of Dental and Craniofacial Research (NIDCR) under the federal Oral Diseases and Disorders Research program (CFDA 93.121). The grant supports research conducted by a collaborative partnership between Henry Ford Health and Michigan State University Health Sciences to investigate mechanisms by which human papillomavirus (HPV) drives immune evasion in head and neck squamous cell carcinomas (HNSCC). The research aims...
- This federal Project Grant award of $1,899,042.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research at the University of Pittsburgh to analyze high-dimensional genomic datasets to reveal mechanistic insights on divergent outcomes of head and neck cancer. The project aims to use existing public databases of human head and neck squamous cell carcinomas (HNSCC) to identify new mechanisms...
- This federal Project Grant award of $249,000.00, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to develop a novel patient-derived tumor organoid (tumoroid) platform for precision treatment of head and neck squamous cell carcinomas (HNSCCS). The key products and services to be delivered include: Establishing a high-throughput automated HNSCC tumoroid platform to capture tumor...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $716,123 Project Grant to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida. The grant, awarded on September 8, 2025, aims to establish a clinical cohort and develop novel analytical methodologies to validate, discover, and optimize non-invasive liquid biopsy tests for prognosis prediction in head and neck squamous cell carcinoma (HNSCC) patients. The project will focus on analyzing circulating cell-free DNA methylation and peripheral immune cell DNA methylation biomarkers to enhance the precision of prognostic predictions for HNSCC, a prevalent and aggressive cancer with poor 5-year survival rates. The grant has an ultimate completion date of May 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $716.1k | 9/8/25 |